<?xml version="1.0" encoding="UTF-8" standalone="yes"?>
<References xsi:schemaLocation="http://www.iedb.org/schema/CurationSchema http://beta.iedb.org/schema/Curation.xsd" xmlns="http://www.iedb.org/schema/CurationSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <Reference>
        <ReferenceId>1338</ReferenceId>
        <DateLastUpdated>2020-09-10-07:00</DateLastUpdated>
        <Article>
            <PubmedId>11803063</PubmedId>
            <Abstract>Recombinant replication-defective adenovirus expressing the CS gene from Plasmodium berghei (Ad-PbCS) was found to induce a strong CD8(+) T cell response after intra-dermal or -muscular immunisation. Boosting of an adenovirus-primed immune response with the replication-impaired poxvirus, modified vaccinia virus Ankara (MVA) led to enhanced immunogenicity and substantial protective efficacy. The recombinant adenoviral vaccine was capable of boosting to protective levels a CD8(+) T cell response primed by either a plasmid DNA vaccine, a recombinant Ty virus-like particle vaccine or recombinant MVA each expressing the same epitope or antigen. Complete protective efficacy after intradermal immunisation was observed with the adenovirus prime-MVA boost regime. This study identifies recombinant replication-defective adenovirus as an alternative to recombinant replication-defective poxviruses as boosting agents for the induction of strong protective CD8(+) T cell responses.</Abstract>
            <ArticleYear>2002</ArticleYear>
            <ArticlePages>1039-45</ArticlePages>
            <ArticleTitle>Enhanced CD8 T cell immunogenicity and protective efficacy in a mouse malaria model using a recombinant adenoviral vaccine in heterologous prime-boost immunisation regimes.</ArticleTitle>
            <Authors>
                <Author>
                    <LastName>Gilbert</LastName>
                    <ForeName>Sarah C</ForeName>
                </Author>
                <Author>
                    <LastName>Schneider</LastName>
                    <ForeName>JÃ¶rg</ForeName>
                </Author>
                <Author>
                    <LastName>Hannan</LastName>
                    <ForeName>Carolyn M</ForeName>
                </Author>
                <Author>
                    <LastName>Hu</LastName>
                    <ForeName>Jiang Ting</ForeName>
                </Author>
                <Author>
                    <LastName>Plebanski</LastName>
                    <ForeName>Magdalena</ForeName>
                </Author>
                <Author>
                    <LastName>Sinden</LastName>
                    <ForeName>Robert</ForeName>
                </Author>
                <Author>
                    <LastName>Hill</LastName>
                    <ForeName>Adrian V S</ForeName>
                </Author>
            </Authors>
            <Affiliations>Wellcome Trust Centre for Human Genetics, University of Oxford, Roosevelt Drive, OX3 7BN, Oxford, UK. sarah.gilbert@well.ox.ac.uk.</Affiliations>
            <ArticleChemicalList>Malaria Vaccines;Vaccines, DNA;Vaccines, Synthetic</ArticleChemicalList>
            <ArticleMeshHeadingsList>Adenoviridae(genetics); Animals; CD8-Positive T-Lymphocytes(immunology); Female; Immunization, Secondary; Malaria(prevention &amp; control); Malaria Vaccines(immunology); Mice; Mice, Inbred BALB C; Vaccines, DNA(immunology); Vaccines, Synthetic(immunology); Vaccinia virus(genetics)</ArticleMeshHeadingsList>
            <Journal>
                <Volume>20</Volume>
                <Issue>7-8</Issue>
                <Title>Vaccine</Title>
                <Issn>1873-2518</Issn>
                <MedlineTa>Vaccine</MedlineTa>
            </Journal>
        </Article>
        <Epitopes>
            <Epitope>
                <EpitopeName>pb9</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>SYIPSAEKI</LinearSequence>
                        <StartingPosition>252</StartingPosition>
                        <EndingPosition>260</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>P06915.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>5821</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Figure 1</LocationOfData>
                <EpitopeId>62604</EpitopeId>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Exact Epitope</EpitopeStructureDefines>
                <Assays>
                    <TCell>
                        <LocationOfData>Figures 1, 2 and 3</LocationOfData>
                        <TCellId>21053</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10090</OrganismId>
                                <Sex>F</Sex>
                                <Age>4-6 weeks</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Antigen</EpitopeRelation>
                                    <Object>
                                        <AccessionSequenceMolecule>
                                            <ChemicalType>Protein</ChemicalType>
                                            <Molecule>
                                                <GenBankId>P06915.1</GenBankId>
                                            </Molecule>
                                            <SourceOrganismId>5821</SourceOrganismId>
                                        </AccessionSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Circumsporozoite protein precursor (CS)</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <ImmunogenContainingObject>
                                    <RecombinantOrganism>
                                        <SubType>Recombinant Organism</SubType>
                                        <RecombinantOrganismId>10535</RecombinantOrganismId>
                                    </RecombinantOrganism>
                                </ImmunogenContainingObject>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 dose(s) of 50 ug DNA, 1000000 pfu MVA or 10000000 pfu adenovirus</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Up to 3 immunizations (homologous as well as heterologous) were administered. Routes used were intranasal, intramuscular, intradermal, subcutaneous and gene-painted. Spleen cells were collected 10 days after the last immunization.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>T cell CD8+</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Splenocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>124</MhcAlleleId>
                            <MhcEvidenceCode>Not determined</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>pb9</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>SYIPSAEKI</LinearSequence>
                                        <StartingPosition>252</StartingPosition>
                                        <EndingPosition>260</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>P06915.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>5821</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>48</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <AssayComments>With single immunizations of an adenovirus vector delivered via various routes, the intradermal route gave the highest T-cell response while gene paint" groups (ear, abdomen) gave undetectable responses. Multiple homologous and heterologous immunizations using adenovirus, modified vaccinia virus Ankara (MVA) and plasmid DNA as vectors increased the T-cell response (especially for adenovirus primed-MVA boosted and DNA primed-Adenovirus/MVA or MVA/Adenovirus boosted).".</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
            </Epitope>
        </Epitopes>
    </Reference>
</References>

